Nektar Therapeutics (NASDAQ:NKTR) has a beta value of 0.66 and has seen 0.86 million shares traded in the recent trading session. The company, currently valued at $126.55M, closed the recent trade at $0.68 per share which meant it lost -$0.06 on the day or -7.90% during that session. The NKTR stock price is -183.82% off its 52-week high price of $1.93 and 4.41% above the 52-week low of $0.65. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.46 million shares traded. The 3-month trading volume is 2.03 million shares.
The consensus among analysts is that Nektar Therapeutics (NKTR) is Buy stock at the moment, with a recommendation rating of 2.11. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 1 out of 3 have rated it as a Hold, with 2 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.18.
Nektar Therapeutics (NASDAQ:NKTR) trade information
Sporting -7.90% in the red today, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the NKTR stock price touched $0.68 or saw a rise of 23.6%. Year-to-date, Nektar Therapeutics shares have moved -26.88%, while the 5-day performance has seen it change -20.99%. Over the past 30 days, the shares of Nektar Therapeutics (NASDAQ:NKTR) have changed -19.05%. Short interest in the company has seen 6.95 million shares shorted with days to cover at 3.38.
Wall Street analysts have a consensus price target for the stock at $18.5, which means that the shares’ value could jump 96.32% from the levels at last check today.. The projected low price target is $6.0 while the price target rests at a high of $24.0. In that case, then, we find that the latest price level in today’s session is -3429.41% off the targeted high while a plunge would see the stock gain -782.35% from the levels at last check today..
Nektar Therapeutics (NKTR) estimates and forecasts
The company’s shares have lost -38.74% over the past 6 months. Revenue growth from the last financial year stood is estimated to be -36.41%.
9 analysts offering their estimates for the company have set an average revenue estimate of 15.61M for the current quarter. 9 have an estimated revenue figure of 15.7M for the next ending quarter. Year-ago sales stood 21.64M and 23.49M respectively for this quarter and the next, and analysts expect sales will shrink by -27.88% for the current quarter and -36.41% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 25.49% over the past 5 years. Earnings growth for 2025 is a modest -8.45% while over the next 5 years, the company’s earnings are expected to decrease by -11.68%.
NKTR Dividends
Nektar Therapeutics is expected to release its next earnings report on 2025-Mar-11 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Nektar Therapeutics (NASDAQ:NKTR)’s Major holders
Insiders own 1.26% of the company shares, while shares held by institutions stand at 71.87% with a share float percentage of 72.79%. Investors are also buoyed by the number of investors in a company, with Nektar Therapeutics having a total of 180.0 institutions that hold shares in the company. The top two institutional holders are DEEP TRACK CAPITAL, LP with over 17.88 million shares worth more than $22.17 million. As of 2024-06-30, DEEP TRACK CAPITAL, LP held 8.5599% of shares outstanding.
The other major institutional holder is BLACKROCK INC., with the holding of over 15.16 million shares as of 2024-06-30. The firm’s total holdings are worth over $18.79 million and represent 7.2575% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are MUTUAL FUND SERIES TRUST-Eventide Healthcare & Life Sciences Fund and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund . As of Dec 31, 2024 , the former fund manager holds about 3.57% shares in the company for having 6.65 shares of worth $4.47 million while later fund manager owns 5.72 shares of worth $3.85 million as of Dec 31, 2024 , which makes it owner of about 3.08% of company’s outstanding stock.
